10 likes | 26 Views
Smoking Cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, and others. <br><br>The total diagnosed prevalent population of Smoking Cessation in the 7MM was 49,301,950 in 2017. The diagnosed prevalent cases of smokers in the United Kingdom was found to be 7,750,777 while Germany and France had 19,305,099 and 14,044,812 diagnosed prevalent cases respectively in 2017.<br><br>As per the Delveinsight, the market size of Smoking Cessation in the 7MM was found to be USD 2,874.8 million in 2017, which is expected to increase during the forecast period. <br><br>Increase in awareness, government-mandated warnings on tobacco products, research and development are some of the key drivers for Smoking Cessation market. <br><br>The key companies in the Smoking Cessation Market include Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, Smoke Free Therapeutics (NFL Biosciences SAS), Novo Nordisk and many others.<br><br>For more details, visit: https://www.delveinsight.com/report-store/smoking-cessation-market<br><br>Source: Smoking Cessation Market Landscape<br><br>
E N D